首页> 外文期刊>Scientific reports. >A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
【24h】

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

机译:癌症临床测序中知识策疗系统策划内容的比较研究

获取原文
           

摘要

Medical oncologists are challenged to personalize medicine with scientific evidence, drug approvals, and treatment guidelines based on sequencing of clinical samples using next generation sequencer (NGS). Knowledge-based curation systems have the potential to help address this challenge. We report here the results of examining the level of evidence regarding treatment approval and clinical trials between recommendations made by Watson for Genomics (WfG), QIAGEN Clinical Insight Interpret (QCII), and Oncomine knowledge-based reporter (OKR). The tumor samples obtained from the solid cancer patients between May to June 2018 at Kindai University Hospital. The formalin-fixed paraffin-embedded tumor samples (n?=?31) were sequenced using Oncomine Comprehensive Assay v3. Variants including copy number alteration and gene fusions identified by the Ion reporter software were used commonly on three curation systems. Curation process of data were provided for 25 solid cancers using three curation systems independently. Concordance and distribution of curated evidence levels of variants were analyzed. As a result of sequencing analysis, nonsynonymous mutation (n?=?58), gene fusion (n?=?2) or copy number variants (n?=?12) were detected in 25 cases, and subsequently subjected to knowledge-based curation systems (WfG, OKR, and QCII). The number of curated information in any systems was 51/72 variants. Concordance of evidence levels was 65.3% between WfG and OKR, 56.9% between WfG and QCII, and 66.7% between OKR and QCII. WfG provided great number of clinical trials for the variants. The annotation of resistance information was also observed. Larger differences were observed in clinical trial matching which could be due to differences in the filtering process among three curation systems. This study demonstrates knowledge-based curation systems (WfG, OKR, and QCII) could be helpful tool for solid cancer treatment decision making. Difference in non-concordant evidence levels was observed between three curation systems, especially in the information of clinical trials. This point will be improved by standardized filtering procedure and enriched database of clinical trials in Japan.
机译:医疗肿瘤学家根据使用下一代序列仪(NGS)的临床样品的测序来个性化药物,以临床样本的测序来个性化医学。基于知识的策策系统有可能帮助解决这一挑战。我们在此报告了审查有关Watson对基因组学(WFG),QIAGEN临床洞察解释(QCII)和数学知识的报告(OKR)所作建议之间的审批和临床试验之间的结果。在2018年6月至2018年6月在林大大学医院获得的肿瘤样品。使用Oncomine综合测定v3对福尔马林固定的石蜡包埋的肿瘤样品(n?=Δ31)进行测序。包括离子报告软件鉴定的拷贝数改变和基因融合的变体通常在三种策择系统上使用。使用三种策粒系统独立地为25种固体癌提供数据的策序方法。分析了策划证据水平的协调和分布。作为测序分析的结果,在25例中检测到基因匿名突变(n?=α58),基因融合(n?=Δ2)或拷贝数变体(n?=Δ12),随后对知识为基础策施系统(WFG,OKR和QCII)。任何系统中的策划信息数量为51/72变体。 WFG和OKR之间的证据水平的一致性程度为65.3%,WFG和QCII之间的56.9%,OKR和QCII之间的66.7%。 WFG为变种提供了大量的临床试验。还观察到阻力信息的注释。在临床试验匹配中观察到更大的差异,这可能是由于三种策择系统中的过滤过程的差异。本研究证明了基于知识的策策系统(WFG,OKR和QCII)可以有用的纯癌症治疗决策工具。在三种策策系统之间观察到非协调证据水平的差异,特别是在临床试验的信息中。这一点将通过标准化过滤程序和日本临床试验数据库改善。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号